Santen Pharmaceutical Co., Ltd

(OTCGREY:SNPHF)

Latest On Santen Pharmaceutical Co., Ltd (SNPHF):

Date/Time Type Description Signal Details
2021-03-30 06:08 ESTDividendA dividend of $14 has been announced on May 8, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021.Neutral
2021-02-10 21:34 ESTFinancialsCompany financials have been released.Neutral
2021-02-05 05:32 ESTEarnings EstimateAn EPS average of $0.18 is estimated for the quarter ending on June 30, 2021.Buy
2020-11-26 23:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-09 22:29 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 02:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 18:30 ESTFinancialsCompany financials have been released.Neutral
2020-10-27 07:28 ESTNewsFDA accepts Santen application for severe allergic eye diseaseN/A
2020-09-26 15:22 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 07:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 11:25 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 02:33 ESTEarnings EstimateAn EPS average of $0.14 is estimated for the quarter ending on September 30, 2020.Sell
2020-08-07 02:33 ESTEarnings EstimateAn EPS average of $0.88 is estimated for the 2022 year.Buy
2020-08-07 02:33 ESTEarnings EstimateAn EPS average of $0.74 is estimated for the 2021 year.Buy
2020-08-07 02:33 ESTEarnings EstimateAn EPS average of $0.15 is estimated for the quarter ending on December 31, 2020.N/A
2020-08-06 22:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 15:00 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 10:46 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 19:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 07:09 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 23:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 15:01 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 19:48 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 11:13 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 18:55 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 02:43 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 14:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 06:56 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 08:30 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 07:33 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 03:14 ESTFinancialsCompany financials have been released.Neutral
2020-05-09 22:43 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 07:50 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 18:44 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 06:32 ESTFinancialsCompany financials have been released.Neutral
2020-04-09 22:38 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 23:07 ESTFinancialsCompany financials have been released.Neutral
2020-03-30 06:12 ESTDividendA dividend of $14 has been announced on May 9, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020.Neutral
2020-03-25 22:38 ESTFinancialsCompany financials have been released.Neutral
2020-03-03 10:36 ESTStock SplitA stock split has occured on Mar 27, 2015 with a split factor of 5:1.Neutral
2020-02-28 06:12 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 00:14 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 01:46 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 01:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 01:32 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 01:46 ESTFinancialsCompany financials have been released.Neutral
2020-02-11 20:37 ESTEarnings EstimateAn EPS average of $0.67 is estimated for the 2020 year.Buy

About Santen Pharmaceutical Co., Ltd (SNPHF):

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

See Advanced Chart

General

  • Name Santen Pharmaceutical Co., Ltd
  • Symbol SNPHF
  • Type Common Stock
  • Exchange OTCGREY
  • Currency USD
  • Country USA
  • Full Time Employees 4,108
  • Last Split Factor5:1
  • Last Split Date2015-03-27
  • Fiscal Year EndMarch
  • Web URLhttp://www.santen.com
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.69
  • Next Year EPS Estimate $0.77
  • Next Quarter EPS Estimate $0.06
  • Profit Margin 10%
  • Return on Assets 6%
  • Return on Equity 7%
  • Revenue Per Share $0
  • Gross Profit 146.72 billion
  • Quarterly Earnings Growth -1.1%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 34.61
  • Environment Score 5.76
  • Social Score 20.04
  • Governance Score 17.81
  • Controversy Level 0
View More

Highlights

  • Market Capitalization 5.52 billion
  • PEG Ratio 20398.6
View More

Share Statistics

  • Shares Outstanding 407.09 million
  • Shares Float 390.22 million
  • % Held by Insiders 389%
  • % Held by Institutions 44.94%
View More

Technicals

  • Beta 0.35
  • 52 Week High $20.15
  • 52 Week Low $13.2
  • 50 Day Moving Average 15.08
  • 200 Day Moving Average 17.11
View More

Dividends

  • Forward Annual Dividend Yield 0.71%
  • Payout Ratio 39%
  • Dividend Date 2018-06-27
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Santen Pharmaceutical Co., Ltd (SNPHF) Dividend Calendar:

SNPHF's last dividend payment was made to shareholders on June 27, 2018.
Santen Pharmaceutical Co., Ltd pays out 39% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount
2020-09-292020-11-302020-09-302020-05-08$14
2020-03-302020-06-252020-03-312019-05-09$14
2019-09-272019-11-292019-09-302019-05-09$13
2019-03-292019-06-262019-03-312018-05-09$13
2018-09-282018-11-302018-09-302018-05-09$13
2018-03-292018-06-272018-03-312017-05-10$13
2017-03-302017-06-262017-03-312016-08-02$13
2016-09-292016-11-302016-09-302016-08-02$13
2016-03-302016-06-272016-03-312015-05-12$13
2021-03-300000-00-002021-03-312020-05-08$14
2020-03-302020-03-312019-05-09$14

Santen Pharmaceutical Co., Ltd (SNPHF) Earnings Estimates:

An earnings estimate is an analyst's estimate for a company's future quarterly or annual earnings per share (EPS). Future earnings estimates are arguably the most important data when attempting to value a firm.

SNPHF's EPS estimate for the current year is $0.69
Date Number of Analysts Average Estimate Low Estimate High Estimate
2021-06-301$0.18$0.18$0.18

Santen Pharmaceutical Co., Ltd (SNPHF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

SNPHF's next estimated earnings release date is June 30, 2021.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.17$0.1154.55%
2020-09-302020-12-31$N/A$0.18$15.00-98.82%
2020-06-302020-09-30$N/A$0.18$16.90-98.93%
2020-03-312020-06-30$N/A$0.14
2019-12-312020-03-31$585.05 million$0.08
2019-09-302019-12-31$551.8 million$0.16
2019-06-302019-09-30$545.31 million$0.16
2019-03-312019-06-30$546.15 million$0.15
2018-12-312019-03-31$537.22 million$0.19
2018-09-302018-12-31$507.89 million$0.20
2018-06-302018-09-30$509.34 million$0.16$22.60-99.28%
2018-03-312018-06-30$532.13 million$0.15
2017-12-312018-03-31$513.22 million$0.18
2017-09-302017-12-31$486.2 million$0.26
2017-06-302017-09-30$55.95 billion$0.14$19.70-99.31%
2017-03-312017-06-30$48.43 billion$0.20
2016-12-312017-03-31$52.84 billion$0.07
2016-09-302016-12-31$0.15
2016-06-302016-09-30$0.13
2016-03-312016-06-30$0.17
2015-12-312016-03-31$0.07
2015-09-302015-12-31$0.12
2015-06-302015-09-30$0.73$0.00
2015-03-312015-06-30$0.15$10.54-98.59%
2014-12-312015-03-31$0.16$0.00
2014-09-302014-12-31$0.14$0.00
2014-06-302014-09-30$0.12$10.18-98.84%
2014-03-312014-06-30$0.09$0.00
2013-12-312014-03-31$0.04$0.00
2013-09-302013-12-31$0.15$0.00
2013-06-302013-09-30$0.08$0.00
2013-03-312013-06-30$0.14$0.00
2012-12-312013-03-31$0.06$0.00
2012-09-302012-12-31$0.14$0.00
2012-06-302012-09-30$0.14$0.00
2012-03-312012-06-30$0.12$0.00
2011-12-312012-03-31$0.07$0.00
2011-09-302011-12-31$0.14$0.00
2011-06-302011-09-30$0.13$0.00
2011-03-312011-06-30$0.16$0.00
2010-12-312011-03-31$0.19$0.00
2010-09-302010-12-31$0.16$0.00

Santen Pharmaceutical Co., Ltd (SNPHF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Santen Pharmaceutical Co., Ltd (SNPHF) Chart:

Santen Pharmaceutical Co., Ltd (SNPHF) News:

Below you will find a list of latest news for Santen Pharmaceutical Co., Ltd (SNPHF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Santen Pharmaceutical Co., Ltd (SNPHF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Santen Pharmaceutical Co., Ltd (SNPHF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2010-09-10F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000101915510000330/0001019155-10-000330-index.htm
2015-03-30F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1501108/000101915515000133/0001019155-15-000133-index.htm
2013-01-30F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000119380513000146/0001193805-13-000146-index.htm
2013-02-01F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000119380513000182/0001193805-13-000182-index.htm
2015-03-24F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1501108/000119380515000425/0001193805-15-000425-index.htm
2015-04-15F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1501108/000119380515000577/0001193805-15-000577-index.htm
2016-03-07F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000119380516002774/0001193805-16-002774-index.htm
2017-09-29F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1501108/000119380517002951/0001193805-17-002951-index.htm
2019-11-22F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000119380519001509/0001193805-19-001509-index.htm
2014-10-16F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1501108/000157104914005155/0001571049-14-005155-index.htm